Pitted against more established balloon-expandable Sapien 3 valves in TAVR for severe aortic stenosis, the Myval devices ...

Provider groups and health systems warn tariffs will test healthcare’s fragile supply chain, threatening to disrupt patient ...

This was the stock's second consecutive day of gains.

Medtronic, Abbott and Boston Scientific provided updates on their devices used in heart valve disease treatment at the event.

Edwards Lifesciences, the leading global structural heart innovation company, today announced the appointment of Emmet Kelly ...

A new method of alerting clinical care providers holds promise for increasing treatment and improving survival for patients with severe aortic ...

Edwards Lifesciences (NYSE:EW) recently announced significant findings at the ACC Annual Scientific Session, showcasing crucial research in the treatment of structural heart disease. This development, ...

Sands Capital, an investment management company, released its “Sands Capital Select Growth Fund” Q4 2024 investor letter. A ...

Results from the EARLY TAVR trial — the first randomized, controlled FDA pivotal study designed to determine the best ...

Champions of tricuspid transcatheter edge-to-edge repair (TEER) were buoyed by 2-year results of the TRILUMINATE trial ...

A new method of alerting clinical care providers holds promise for increasing treatment and improving survival for patients with severe aortic stenosis (AS), a valvular heart condition that can be ...

Don’t wait. Edwards Lifesciences Corp.’s additional insights from the Early TAVR trial showed a clear benefit for transcatheter aortic valve replacement (TAVR) in patients with asymptomatic aortic ...